ArticleIranian journal of pathology2026
Upregulation of the HOXA10-AS1 LncRNA in Gastric Cancer: An Expression and Bioinformatics Analysis.
Article in Iranian journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objective: Gastric cancer (GC) is a lethal disease with poor prognosis. Long non-coding RNAs (lncRNAs) involved in the development of cancer through changes in their expression levels. In present study, we aimed to evaluate HOXA10-AS gene expression and its potential as a biomarker in GC. Methods: In this study 60 subjects (30 gastric carcinoma tissues and 30 adjacent non-carcinoma tissues) were examined. The expression level of the HOXA10-AS gene was evaluated using quantitative PCR. Furthermore, clinicopathological characteristicswere taken into consideration. Diagnostic value of the HOXA10-AS was examined by ROC curve analysis. Bioinformatics analysis was performed using different databases. Results: Expression of HOXA10-AS was significantly upregulated in GC tumoral tissues. Roc curve analysis revealed that the diagnostic power of HOXA10-AS was high (AUC = 0.64) in the tumor compared to the normal GC tissues. Conclusion: Our findings show that HOXA10-AS expression level is higher in the GC tumor compared to the adjacent non-carcinoma tissues and can act as a strong diagnostic biomarker in GC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.